Ruben Tommasi

Company: Dunad Therapeutics

Job title: Chief Scientific Officer


Advances in Covalent Therapeutics 3:45 pm

Outlining the most recent advances in chemoproteomic techniques used to identify nucleophiles in tractable binding pockets Providing an overview of the state-of-the-art covalent warhead modalities used for targeting non-cysteine nucleophilic residues Describing advancements in Dunad Therapeutics’ novel monovalent covalent degrader platform, and how it can be applied to unlock new target space for the fieldRead more

day: Day 2 PM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.